KBC Group
AMRX icon

KBC Group’s Amneal Pharmaceuticals AMRX Stock Holding History

KBC Group’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$111K Hold
6,417
– – ﹤0.01% 1354
2026
Q1 		$80K Buy
+6,417
New +$86.2K ﹤0.01% 1453
2019
Q4 		– Sell
-55,579
Closed -$161K – 1493
2019
Q3 		$161K Buy
+55,579
New +$194K ﹤0.01% 1283

Other funds holding AMRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

KBC Group's AMRX Position: Q2 2026 in Review

KBC Group held its Amneal Pharmaceuticals (AMRX) position steady in Q2 2026 at 6,417 shares worth $111K. The position accounts for ﹤0.01% of the portfolio, ranked #1354.

KBC Group first reported a position in AMRX in Q3 2019 and has held it in 3 quarters since. The position peaked at $161K in Q3 2019. 311 funds tracked by Wall St. Rank hold AMRX as of Q2 2026.

  • KBC Group held 6,417 shares of Amneal Pharmaceuticals worth $111K as of Q2 2026.
  • KBC Group left its Amneal Pharmaceuticals share count unchanged in Q2 2026.
  • Amneal Pharmaceuticals made up ﹤0.01% of KBC Group's portfolio in Q2 2026, its #1354 holding.
  • KBC Group first reported a position in Amneal Pharmaceuticals in Q3 2019 and has held it in 3 quarters since.
  • KBC Group's Amneal Pharmaceuticals position peaked at $161K in Q3 2019.
  • 311 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2026.

Based on KBC Group's 13F filing for Q2 2026, filed 5 Aug 2026.